We show that vaccine-elicited neutralizing activity is reduced against delta and kappa and even more against delta+ relative to the vaccine-matched pseudovirus. Delta+ reduces neutralization ~ to B.1.351 (beta) which has the greatest magnitude of immune evasion thus far.
2/9
Half of the J&J-vaccinated individuals in our panel had no residual variant neutralization. Although we only analyzed neutralizing antibodies (T cells are also key players for in vivo protection), this supports offering second vaccine dose
#CryoEM structures of the delta and kappa spikes provide blueprints to understand immune evasion, including loss of neutralization by some clinical antibodies whereas sotrovimab (S309) remain efficacious against these variants.
4/9
We reveal that remodeling of the delta and kappa spike NTDs (including a spectacular refolding of the delta NTD) is responsible for the loss of neutralizing activity of most NTD-specific antibodies against these two variants.
5/9
The ACE2-binding affinity of delta and kappa is not markedly different whereas delta+ is significantly reduced relative to ancestral virus, in line with our structural data.
6/9
We propose that increased membrane fusion (as a result of the P681R mutation) is a main factor explaining the fitness advantage of these two variants, as recently shown by @GuptaR_lab , @SystemsVirology & @OlivierSchwartz
7/9
We found a new class of NTD neutralizing antibodies cross-reacting with several #SARSCoV2 variants through recognition of a previously uncharacterized epitope partially overlapping with the NTD antigenic supersite, revealing a possible target for vaccine development.
The #SARSCoV2 CAL20.C (B.1.427/B.1.429) variant is skyrocketing in California. We describe how it evades the host immune response with @DavideCorti6@LucaPiccoli9
The #SARSCoV2 CAL20.C (B.1.427/B.1.429) variant comprises 3 spike mutations: S13I, W152C & L452R reducing plasma neutralizing activity by ~3x and ~5x for vaccine- and infection-elicited antibodies (Abs), compared to the 'ancestral' virus.
2/7
The neutralization potency of 1/3 of RBD Abs is reduced or abrogated by the L452R spike mutation present in #SARSCoV2 CAL20.C (B.1.427/B.1.429), including clinical-stage antibodies such as Eli Lilly LY-CoV555 (bamlanivimab) & Celltrion CT-P59 (regdanvimab)
We report an analysis of #SARSCoV2 spike NTD antigenic sites targeted by monoclonal antibodies (mAbs) in #COVID19 patients in collaboration with @DavideCorti6 and Matteo Samuele Pizzuto @Vir_Biotech
We found that NTD-specific mAbs account for 6-20% of mAbs cloned from memory B cells in #COVID19 patients and that the most potent of them neutralize #SARSCoV2 as efficiently as ultrapotent RBD-specific mAbs and trigger Fc-mediated effector functions effectively.
2/10
We delineated an antigenic map of the #SARSCoV2 spike NTD using #cryoEM (including a 2.2Å structure) and binding assays revealing the presence of a site of vulnerability recognized by all potently neutralizing mAbs described thus far.
We discovered a neutralizing mouse monoclonal antibody (B6) targeting the coronavirus spike fusion machinery (S2 subunit) in collaboration with @McGuire_Lab
We identified by cryoEM that B6 recognizes the spike stem helix and cross-reacts with at least 8 distinct coronavirus spikes including those of the three highly pathogenic (#SARSCoV2, SARS-CoV and MERS-CoV) and the two endemic (OC43 and HKU1) human β-coronaviruses.
2/6
B6 broadly neutralizes spike-mediated entry into cells of distantly related coronaviruses including OC43 (lineage A) as well as MERS-CoV and HKU4 (lineage C) with comparable potencies.
The peer-reviewed version of our article describing the design and evaluation of a multivalent #SARSCoV2 receptor-binding domain #COVID19 vaccine is out!
Based on our previous studies of the immune response to coronavirus infections, we identified that the receptor-binding domain is immunodominant and accounts for most of the neutralizing activity in convalescent plasma/sera.
We therefore reached out to @KingLabIPD who had recently developed a self-assembling two component protein nanoparticle platform allowing to multivalently display respiratory syncytial virus F that elicit high-titers of neutralizing antibodies.